Eli Lilly — News Releases Health Press Releases — RSS Feed & Live Monitoring
PPN World tracks the Eli Lilly — News Releases RSS feed in real time — 5 releases indexed over the last 30 days, the newest arrived 2 d ago. Follow it with saved-search alerts, AI summaries, and full-text search, or plug the RSS URL below into your own reader.
Eli Lilly — News Releases RSS feed URL
https://investor.lilly.com/rss/news-releases.xml?items=10About this feed
Eli Lilly — News Releases is one of the 1000+ press-release feeds PPN World monitors around the clock — an English-language wire focused on Health, filed under United States in our country index. Every release is deduplicated, geotagged, and enriched with an AI summary, and you can attach saved-search alerts to any keyword it publishes. Eli Lilly — News Releases is a low-volume specialist wire — 5 releases over the last 30 days: the kind of source worth an alert rather than a scroll.
How to follow Eli Lilly — News Releases press releases
- Copy the Eli Lilly — News Releases RSS feed URL shown above.
- Paste it into any RSS reader (Feedly, Inoreader, NetNewsWire…) to get the raw feed.
- Or track Eli Lilly — News Releases in PPN World to add deduplication, saved-search alerts, and AI summaries across all 1000+ wires.
Latest Eli Lilly — News Releases press releases
- Lilly confirms date and conference call for second-quarter 2026 financial results announcement2 d ago
INDIANAPOLIS, July 22, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2026 financial results on August 5, 2026. Lilly will also conduct a conference call that…
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions9 d ago
AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly's neuroscience pipeline to address some of the most challenging…
- Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment16 d ago
Analyses across Kisunla (donanemab-azbt) trials providing further insights into the benefit-risk profile from long-term extension data New data compares the diagnostic performance of P-tau217 blood te…
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy29 d ago
The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society of Hematology Annual Meeting and published in The Jo…
- Lilly launches “The Memory Radio Station” across Europe, inviting the public to visually reconstruct fading memories through GenAI29 d ago
New multi-country campaign launches in Geneva alongside the European Academy of Neurology Congress GENEVA, SWITZERLAND, June 26, 2026 -- Today, Eli Lilly and Company (NYSE: LLY) launches The Memory Ra…
- What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management30 d ago
A new Medicare pathway, the Medicare GLP-1 Bridge program, makes Lilly's obesity medicines – a daily pill or the number 1 most prescribed injectable – accessible to eligible Medicare Part D patients b…
- Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders30 d ago
INDIANAPOLIS, June 24, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Centessa Pharmaceuticals plc. Centessa is a clinical-stage…
- Lilly declares third-quarter 2026 dividend32 d ago
INDIANAPOLIS, June 22, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2026 of $1.73 per share on outstanding common s…
- Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL41 d ago
BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients previously treated with a covalent BTK inhibitor…
The newest releases on this wire stream live for PPN World members.